StockpollyBeta
Get App
Popularity #2,998
AUTL · NASDAQ · Biotechnology

Autolus Therapeutics (ADR) (AUTL)

Commercializes AUCATZYL while developing programmed T-cell therapies for cancer and autoimmune diseases.

$2.03
After hours−0.01 (−0.44%)
At close$2.04(+5.15%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue001000092121242646
Cost of revenue22201138182429252520
Gross profit−1−280−1−138−9−4−7−1225
4339475968103565864716169
Research & development322531374051272728362128
111416222742303036364041
Selling & marketing00−200−25000000
General & administrative1101822276730303604041
Other expenses0000010000000
Operating income−44−41−39−59−69−241−65−61−72−72−60−44
−2−24−141−13215−314−7−19−115
Interest income43710876124322
Interest expense530191011−311001123113
Other non-operating income−2−6−5−11−1−166−7−14−4−40−8
Income before tax−46−65−53−58−82−26−68−48−79−91−71−39
Income tax expense012—001201−110
Net income from continuing operations−46−77−53−58−82−28−70−48−79−90−72−39
Other adjustments000000000000
Net income−46−77−53−58−82−28−70−48−79−90−72−39
EPS, basic−$0.26−$0.44−$0.24−$0.22−$0.31−$0.10−$0.26−$0.18−$0.30−$0.34−$0.27−$0.15
EPS, diluted−$0.26−$0.44−$0.24−$0.22−$0.31−$0.10−$0.26−$0.18−$0.30−$0.34−$0.27−$0.15
Weighted average shares, basic174174222266266266266266266266266266
Weighted average shares, diluted174174222266266266266266266266266266
EBITDA−41−33−32−44−66−74−56−43−65−66−57−34
Depreciation & amortization122422243332
EBIT−43−35−33−48−68−76−58−48−68−69−60−36